168 related articles for article (PubMed ID: 38351343)
1. Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype.
Dono A; Torres J; Nunez L; Arevalo O; Rodriguez-Quinteros JC; Riascos RF; Kamali A; Tandon N; Ballester LY; Esquenazi Y
J Neurooncol; 2024 Mar; 167(1):99-109. PubMed ID: 38351343
[TBL] [Abstract][Full Text] [Related]
2. The role of
Dono A; Ramesh AV; Wang E; Shah M; Tandon N; Ballester LY; Esquenazi Y
Neurooncol Adv; 2021; 3(1):vdab050. PubMed ID: 34131647
[TBL] [Abstract][Full Text] [Related]
3. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
[TBL] [Abstract][Full Text] [Related]
4. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
[TBL] [Abstract][Full Text] [Related]
5. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.
Barresi V; Simbolo M; Mafficini A; Martini M; Calicchia M; Piredda ML; Ciaparrone C; Bonizzato G; Ammendola S; Caffo M; Pinna G; Sala F; Lawlor RT; Ghimenton C; Scarpa A
Acta Neuropathol Commun; 2021 Dec; 9(1):200. PubMed ID: 34952640
[TBL] [Abstract][Full Text] [Related]
6. MRI Features May Predict Molecular Features of Glioblastoma in
Park CJ; Han K; Kim H; Ahn SS; Choi D; Park YW; Chang JH; Kim SH; Cha S; Lee SK
AJNR Am J Neuroradiol; 2021 Mar; 42(3):448-456. PubMed ID: 33509914
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
[TBL] [Abstract][Full Text] [Related]
8. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
[TBL] [Abstract][Full Text] [Related]
9. MRI characteristics of H3 G34-mutant diffuse hemispheric gliomas and possible differentiation from IDH-wild-type glioblastomas in adolescents and young adults.
Shao H; Gong J; Su X; Chen N; Li S; Yang X; Zhang S; Huang Z; Hu W; Gong Q; Liu Y; Yue Q
J Neurosurg Pediatr; 2024 Mar; 33(3):236-244. PubMed ID: 38157540
[TBL] [Abstract][Full Text] [Related]
10. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
[TBL] [Abstract][Full Text] [Related]
11. Beyond invasive biopsies: using VASARI MRI features to predict grade and molecular parameters in gliomas.
Setyawan NH; Choridah L; Nugroho HA; Malueka RG; Dwianingsih EK
Cancer Imaging; 2024 Jan; 24(1):3. PubMed ID: 38167551
[TBL] [Abstract][Full Text] [Related]
12. Prediction of
Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Ki-67 expression levels in IDH-wildtype glioblastoma using logistic regression modelling of VASARI features.
Bai L; Jiang J; Zhou J
Neurosurg Rev; 2023 Dec; 47(1):20. PubMed ID: 38135816
[TBL] [Abstract][Full Text] [Related]
14. Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review.
Grogan D; Bray DP; Cosgrove M; Boucher A; Erwood A; Linder DF; Mendoza P; Morales B; Pradilla G; Nduom EK; Neill S; Olson JJ; Hoang KB
J Neurooncol; 2022 Mar; 157(1):187-195. PubMed ID: 35212929
[TBL] [Abstract][Full Text] [Related]
15. Predictive role of magnetic resonance imaging in the distinction of isocitrate dehydrogenase (IDH) mutant grade 4 astrocytomas versus glioblastomas.
Halefoglu AM; Camurcuoglu E; Tanik C; Kizilkaya O; Yilmaz A
Acta Radiol; 2023 Jun; 64(6):2074-2086. PubMed ID: 37038636
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
[TBL] [Abstract][Full Text] [Related]
17. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
[TBL] [Abstract][Full Text] [Related]
18. Gamma distribution model of diffusion MRI for evaluating the isocitrate dehydrogenase mutation status of glioblastomas.
Takase H; Togao O; Kikuchi K; Hata N; Hatae R; Chikui T; Tokumori K; Kami Y; Kuga D; Sangatsuda Y; Mizoguchi M; Hiwatashi A; Ishigami K
Br J Radiol; 2022 May; 95(1133):20210392. PubMed ID: 35138915
[TBL] [Abstract][Full Text] [Related]
19. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
[TBL] [Abstract][Full Text] [Related]
20.
Yoon BH; Park JS; Kang S; Kwon NJ; Lee KS; Kim CY; Choe G
Br J Neurosurg; 2023 Oct; 37(5):1233-1236. PubMed ID: 33095064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
